Cargando…

Significant protection from infection and AIDS progression after gastrointestinal and oral vaccinations, respectively, with a SIV DNA/rMVA vaccine

Detalles Bibliográficos
Autores principales:	Aldovini, A, Manrique, M, Cobo-Molinos, A, Kozlowski, P, Carvlle, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441614/ https://www.ncbi.nlm.nih.gov/pubmed/23046632 http://dx.doi.org/10.1186/1742-4690-9-S2-O1

Ejemplares similares

Protection of IFNAR (−/−) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2
por: Jabbar, Tamara Kusay, et al.
Publicado: (2013)

OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial
por: Currier, JR, et al.
Publicado: (2009)

OA07-03. Influence of preexisting vaccinia immunity on a DNA/MVA SIV vaccine, decreased cellular immunity but enhanced control of a pathogenic SIV challenge
por: Kannanganat, S, et al.
Publicado: (2009)

Evidence for Env-V2 sieve effect in breakthrough SIV (MAC251) infections in rhesus monkeys vaccinated with Ad26/MVA and MVA/Ad26 constructs
por: Sina, S, et al.
Publicado: (2012)

Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
por: Ondondo, Beatrice, et al.
Publicado: (2006)

A recombinant attenuated Mycobacterium tuberculosis-SIV combination vaccine is safe and immunogenic in immunocompromised, SIV-infected infant macaques
por: Jensen, K, et al.
Publicado: (2012)

DNA/MVA Vaccines for HIV/AIDS
por: Iyer, Smita S., et al.
Publicado: (2014)

Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2016)

Vaccination with MVA/HIV induces differential recruitment of monocyte subsets into the circulation and monocyte-specific transcriptional programs
por: Andersen-Nissen, E, et al.
Publicado: (2012)

Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
por: Meseda, Clement A., et al.
Publicado: (2016)

Early pro-inflammatory host response to recombinant HSV-SIV vaccination in sooty mangabeys
por: Rout, N, et al.
Publicado: (2012)

Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens
por: Ratto-Kim, Silvia, et al.
Publicado: (2012)

Intra-dermal immunisation with SIV gag-based vaccines alone inhibits acquisition of SIVmac251
por: Almond, N, et al.
Publicado: (2012)

Understanding the benign nature of natural SIV infection: Implications for AIDS pathogenesis
por: Silvestri, Guido
Publicado: (2006)

GM-CSF co-expressing DNA/MVA vaccine, prevention of acquisition by two series of SIVE660 challenges followed by a series of SIV251 challenges
por: Robinson, H, et al.
Publicado: (2012)

Virus-specific cellular immune correlates of survival in vaccinated monkeys after SIV challenge
por: Letvin, Norman
Publicado: (2006)

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys
por: Liu, J, et al.
Publicado: (2012)

Immune complexes can dampen inflammatory signaling at the mucosal surface during protective SIV vaccination
por: Smith, AJ, et al.
Publicado: (2012)

Immune control of an SIV challenge by a heterolgous and direct mucosal vaccination regimen in rhesus monkeys
por: Sun, C, et al.
Publicado: (2012)

Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques
por: Ventura, John D., et al.
Publicado: (2022)

A novel Plasmodium vivax vaccine based on recombinant chimpanzee adenovirus ChAd63 and MVA expressing TRAP
por: Bauza, Karolis, et al.
Publicado: (2012)

Co-expressing GP5 and M proteins under different promoters in recombinant modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV)
por: Zheng, Qisheng, et al.
Publicado: (2007)

Anti-retroviral innate immune responses in multiple lymphoid tissues elicited by protective live attenuated SIV vaccination
por: Mattiuzzo, Giada, et al.
Publicado: (2011)

SIVΔnef vaccination mobilizes systemic and mucosal natural killer cells in Mamu A*01+ macaques
por: Reeves, R, et al.
Publicado: (2012)

OAO5-04. Gp96-Ig-SIV vaccines induce predominant immune responses at mucosal sites
por: Strbo, N, et al.
Publicado: (2009)

Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation
por: Bricker, Katherine M., et al.
Publicado: (2020)

Oral Vaccination Approaches for Anti-SHIV Immunity
por: Velarde de la Cruz, Erandi, et al.
Publicado: (2021)

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C
por: Gómez, C, et al.
Publicado: (2012)

Lv4, an activity that restricts nuclear entry of SIV(MAC)/SIV(SM) in human blood cells
por: Pizzato, Massimo, et al.
Publicado: (2013)

Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use
por: Wahren, Britta, et al.
Publicado: (2006)

The Future of Smallpox Vaccination: is MVA the key?
por: Slifka, Mark K
Publicado: (2005)

CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections
por: Kwa, S, et al.
Publicado: (2012)

P17-20. Lentiviral vector-based vaccine against SIV infection and simian AIDS
por: Beignon, A, et al.
Publicado: (2009)

Acute infection by SIV: massive immunological damage
por: Roederer, Mario
Publicado: (2006)

A novel genotype of MVA that efficiently replicates in single cell suspensions
por: Jordan, Ingo, et al.
Publicado: (2013)

Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Tetherin antagonism by HIV-1 and its SIV precursors
por: Kirchhoff, Frank
Publicado: (2011)

A multiclade DNA/Ad vaccines for AIDS: the present and next generation
por: Nabel, Gary J
Publicado: (2006)

Correction: Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Correction: Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t9od2kktdih4r3ufhrblrcn46m